Physician profile
Simone D Noble
NPI 1659512093
$5,406.31
in general payments reported to CMS, 2019-2025
28 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $1,031 · 2023: $1,372 · 2024: $888 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,449 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.19 |
| Education | $483.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $915.76 | 2022-2025 | |
| Leo Pharma INC. | $769.69 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $682.35 | 2022-2025 | Tremfya, Remicade, Simponi Aria |
| Genzyme Corporation | $374.30 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $367.92 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $361.14 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $359.08 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $320.27 | 2021-2025 | |
| Pfizer INC. | $223.40 | 2021-2025 | |
| Galderma Laboratories, L.P. | $153.22 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $149.19 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $145.85 | 2021-2025 | Cabtreo, Jublia, Duobrii |
| Amgen INC. | $115.61 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $93.03 | 2022-2024 | Taltz, Olumiant |
| Vyne Pharmaceuticals INC. | $76.39 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $54.93 | 2021-2022 | |
| Mission Pharmacal Company | $37.28 | 2021-2022 | |
| Revance Therapeutics, INC. | $35.88 | 2024 | Daxxify |
| Almirall LLC | $28.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $27.13 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.28 | 2024 | Ycanth |
| Sun Pharmaceutical Industries INC. | $16.09 | 2022 | |
| Fresenius Kabi USA, LLC | $15.75 | 2024 | Idacio |
| Dermavant Sciences, INC. | $15.27 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $13.97 | 2023 | |
| Incyte Corporation | $13.27 | 2022 | |
| Organon LLC | $13.13 | 2025 | |
| Journey Medical Corporation | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Noble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.